Patent Cliff

Imagine a toll bridge that has generated enormous, guaranteed revenue for twenty years because it was the only crossing for miles, and then, on one specific date, a dozen free alternative bridges all open at once, and traffic on the original bridge collapses almost overnight. A patent cliff is that exact moment, applied to a blockbuster drug.

A new drug typically enjoys roughly twenty years of patent protection from the date it is filed, which combined with the years spent in clinical trials before approval, leaves a shorter effective period of true market exclusivity once the drug is actually being sold. During that window, the originator company can price the drug without direct generic competition, often generating billions of dollars in annual revenue for a genuine blockbuster.

The moment that patent expires, the cliff arrives. Generic manufacturers, who have often been preparing for years, filing an ANDA and securing regulatory approval in advance, can launch competing versions almost immediately, and the originator's sales for that drug can fall by 70 to 90 percent within months as far cheaper generic alternatives flood the market.

This is precisely the moment India's generics industry, and its ANDA filing expertise covered elsewhere on this site, is built to exploit. Indian companies specialise in being ready, sometimes years in advance, to launch a generic version the instant a major drug's patent cliff arrives, competing on speed to market as much as on eventual price.

Whenever a global pharmaceutical company's quarterly results mention a sharp, specific revenue decline tied to one drug losing exclusivity, that is a patent cliff playing out in real time, and there is a good chance an Indian generics manufacturer is among the companies now selling a cheaper alternative into that same market.